Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
11.44
+0.14 (1.24%)
Mar 13, 2025, 1:09 PM EDT - Market open
Maze Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 25.91 | 24.61 | 22.83 |
| Research & Development | 77.33 | 73.95 | 88.19 |
| Operating Expenses | 103.24 | 98.55 | 111.03 |
| Operating Income | 64.26 | -98.55 | -111.03 |
| Interest & Investment Income | 3.14 | 1.97 | 2.03 |
| Earnings From Equity Investments | - | - | -3.54 |
| EBT Excluding Unusual Items | 67.7 | -96.59 | -112.54 |
| Gain (Loss) on Sale of Investments | - | - | -2.4 |
| Other Unusual Items | -11.02 | -3.83 | - |
| Pretax Income | 56.68 | -100.42 | -114.94 |
| Net Income | 55.23 | -100.42 | -114.94 |
| Net Income to Common | -18.27 | -100.42 | -114.94 |
| Shares Outstanding (Basic) | 23 | 22 | 19 |
| Shares Outstanding (Diluted) | 23 | 22 | 19 |
| Shares Change (YoY) | 17.86% | 13.89% | - |
| EPS (Basic) | -0.80 | -4.55 | -5.93 |
| EPS (Diluted) | -0.80 | -4.55 | -5.93 |
| Free Cash Flow | 77.19 | -87.27 | -101.17 |
| Free Cash Flow Per Share | 3.38 | -3.95 | -5.22 |
| EBITDA | 67.83 | -94.46 | -107.21 |
| D&A For EBITDA | 3.57 | 4.09 | 3.82 |
| EBIT | 64.26 | -98.55 | -111.03 |
Source: S&P Capital IQ. Standard template.
Financial Sources.